Skip to main content
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. — Investor Relations & Filings

Ticker · LXEO ISIN · US52886X1072 US Manufacturing
Open in API
Filings indexed 289 across all filing types
Latest filing 2023-10-31 Regulatory Filings
Country US United States of America
Listing US LXEO

About Lexeo Therapeutics, Inc.

https://www.lexeotx.com/

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to developing gene therapies for genetically defined diseases. The company is advancing a diverse pipeline of investigational adeno-associated virus (AAV)-based gene therapy candidates. Its primary areas of focus are rare cardiovascular diseases and APOE4-associated Alzheimer's disease. Lexeo's strategy centers on addressing conditions with high unmet medical needs by leveraging pioneering science, including research originating from institutions such as Weill Cornell Medicine, to develop treatments with curative potential.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1 for Lexeo Therapeutics, Inc. It is signed by representatives of underwriters. The content is a procedural request related to the registration and offering process, not a financial report or detailed filing. The document length is short (2325 characters) and it does not contain financial data or report content. It is an announcement/request related to a regulatory filing process, specifically concerning a registration statement effectiveness. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and procedural communication.
2023-10-31 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from Lexeo Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references the Securities Act of 1933 and Rule 461, which pertains to registration statements for securities offerings. The document is a formal correspondence related to the registration process for a securities offering, not a financial report, earnings release, or other types of filings. It is a regulatory filing related to the registration process and does not contain financial data or report content itself. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (2048 characters), and it is a letter requesting an action, not a report or announcement of a report publication.
2023-10-31 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement filed with the SEC, dated October 30, 2023, for Lexeo Therapeutics, Inc. It is an amendment to the initial Form S-1 registration statement under the Securities Act of 1933. The content includes a preliminary prospectus for an initial public offering (IPO) of common stock, detailing the offering size, price range, underwriting, risk factors, business overview, management discussion, financial statements, and other related information. This type of filing is a registration statement for securities offering, which is distinct from annual reports, earnings releases, or other financial reports. It is a capital markets filing related to the company's fundraising and public offering of shares. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear identification of the form and content.
2023-10-30 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter from a law firm to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1 filed by Lexeo Therapeutics, Inc. It discusses confidential treatment requests, valuation methodologies for common stock, and details related to the company's initial public offering (IPO) process. The content focuses on accounting policies, fair value determinations, and responses to SEC comments related to the Registration Statement. This is not the Registration Statement itself but a supplemental letter providing additional information and clarifications to the SEC staff. The document is not a financial report like an Annual Report or Interim Report, nor is it a simple announcement or certification. It is a regulatory filing related to the registration process for an IPO, specifically a correspondence letter responding to SEC comments on a Form S-1 registration statement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory communication that does not fit into other specific categories.
2023-10-06 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated September 29, 2023, for Lexeo Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information about the company, its business, risk factors, management, financial condition, and use of proceeds. Form S-1 is a registration statement used for securities offerings, specifically IPOs, and is not a financial report like an annual or quarterly report, nor is it an earnings release or other types of filings listed. The document is a capital markets filing related to fundraising and securities registration. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-09-29 English
Regulatory Filings 2023
Regulatory Filings
2023-09-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.